Earnings ·
MiniMed Group, Inc. reported first-quarter fiscal 2027 results ending July 31, 2026, with worldwide net sales of $843…
MMEDMiniMed Group, Inc.
MiniMed Group, Inc. reported first-quarter fiscal 2027 results ending July 31, 2026, with worldwide net sales of $843 million, representing 16.6% growth as reported and 15.8% organic growth. U.S. net sales reached $240 million (up 13.1%), while international net sales totaled $603 million (up 18.1%). The company raised its fiscal year 2027 organic revenue growth guidance to approximately 10.5%, up from the prior estimate of 10%, and reaffirmed an adjusted EBITDA margin target of approximately 16%. Key operational highlights include the U.S. launch of MiniMed Flex™ with Simplera™, FDA submission for MiniMed Fit™, CE Mark approval for MiniMed Flex™, completion of Vivera™ pivotal trial enrollment, and IDE approval for a next-gen extended wear sensor. MiniMed Group, Inc. operates in the diabetes technology industry, developing insulin delivery systems, continuous glucose monitors, and related algorithms.